--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-24-166275" form_type: "8-K" ticker: null cik: "0001828522" company_name: "eFFECTOR Therapeutics, Inc." filed_at: "2024-06-24T23:59:59+00:00" generated_at: "2026-06-01T02:33:01.908513+00:00" event_type: "other_material" sentiment: "negative" materiality_score: 1.0 calibrated_materiality_score: 1.0 confidence: "high" source: SEC EDGAR --- # eFFECTOR Therapeutics to wind down operations, terminate staff, and delist from Nasdaq ## Summary - Company terminated all employees in connection with a planned wind down of operations. - Expects one-time charges of approximately $0.6 million for severance and related costs in Q2 2024. - All seven directors resigned; Stephen Worland (CEO), Michael Byrnes (CFO), and Douglas Warner (CMO) departed. - Craig Jalbert appointed sole director, CEO, President, Treasurer, and Secretary to manage wind down. - Company plans to voluntarily request delisting of common stock and warrants from Nasdaq. ## SEC filing metadata - accession: 0001193125-24-166275 - form_type: 8-K - cik: 0001828522 - company_name: eFFECTOR Therapeutics, Inc. - filed_at: 2024-06-24T23:59:59+00:00 - event_type: other_material - sentiment: negative - materiality_score: 1.0 - calibrated_materiality_score: 1.0 - confidence: high - sec_items: 2.05, 5.02, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/d860453d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-24-166275 - JSON: https://secwatch.observer/filing/0001193125-24-166275.json - Plain text: https://secwatch.observer/filing/0001193125-24-166275.txt ## Key facts - Executive change Craig R. Jalbert was appointed as sole member of the Board at eFFECTOR Therapeutics, Inc.. - Action: appointed - Role: sole member of the Board source text: On June 21, 2024, the Board appointed Craig R. Jalbert, age 62, as the Company’s CEO, President, Treasurer and Secretary, and sole member of the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm - Executive change Elizabeth P. Bhatt resigned as Director at eFFECTOR Therapeutics, Inc.. - Action: resigned - Role: Director source text: On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm - Executive change Michael Byrnes departed as Chief Financial Officer and Secretary at eFFECTOR Therapeutics, Inc.. - Action: ceased serving - Role: Chief Financial Officer and Secretary source text: On June 21, 2024, Stephen T. Worland, Ph.D., President and CEO, Michael Byrnes, Chief Financial Officer and Secretary, and Douglas Warner, M.D., Chief Medical Officer, ceased serving in their respective officer positions. evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm - Executive change Stephen T. Worland, Ph.D. resigned as Director at eFFECTOR Therapeutics, Inc.. - Action: resigned - Role: Director source text: On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm - Executive change Brian M. Gallagher, Jr., Ph.D. resigned as Director at eFFECTOR Therapeutics, Inc.. - Action: resigned - Role: Director source text: On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm - Executive change Chris Ehrlich resigned as Director at eFFECTOR Therapeutics, Inc.. - Action: resigned - Role: Director source text: On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm - Executive change Craig R. Jalbert was appointed as CEO, President, Treasurer and Secretary at eFFECTOR Therapeutics, Inc.. - Action: appointed - Role: CEO, President, Treasurer and Secretary source text: On June 21, 2024, the Board appointed Craig R. Jalbert, age 62, as the Company’s CEO, President, Treasurer and Secretary, and sole member of the Board. evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm - Executive change Barbara Klencke, M.D. resigned as Director at eFFECTOR Therapeutics, Inc.. - Action: resigned - Role: Director source text: On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm - Executive change Caroline Loewy resigned as Director at eFFECTOR Therapeutics, Inc.. - Action: resigned - Role: Director source text: On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm - Executive change Stephen T. Worland, Ph.D. departed as President and CEO at eFFECTOR Therapeutics, Inc.. - Action: ceased serving - Role: President and CEO source text: On June 21, 2024, Stephen T. Worland, Ph.D., President and CEO, Michael Byrnes, Chief Financial Officer and Secretary, and Douglas Warner, M.D., Chief Medical Officer, ceased serving in their respective officer positions. evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm - Executive change Kristen Harrington-Smith resigned as Director at eFFECTOR Therapeutics, Inc.. - Action: resigned - Role: Director source text: On June 21, 2024, in connection with the planned wind down of the Company’s operations, Brian M. Gallagher, Jr., Ph.D., Elizabeth P. Bhatt, Chris Ehrlich, Kristen Harrington-Smith, Barbara Klencke, M.D., Caroline Loewy and Stephen T. Worland, Ph.D., each notified the Company of their respective resignations as members of the board of directors evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm - Executive change Douglas Warner, M.D. departed as Chief Medical Officer at eFFECTOR Therapeutics, Inc.. - Action: ceased serving - Role: Chief Medical Officer source text: On June 21, 2024, Stephen T. Worland, Ph.D., President and CEO, Michael Byrnes, Chief Financial Officer and Secretary, and Douglas Warner, M.D., Chief Medical Officer, ceased serving in their respective officer positions. evidence_url: https://www.sec.gov/Archives/edgar/data/1828522/000119312524166275/0001193125-24-166275-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.